Author

Feng Li

Auburn UniversityORCID 0000-0002-8559-3831Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Feng Li11 papers · Baylor College of Medicine

Biology Disciplines

Click to filter author papers

Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

Ahmad-Bin Salam· 1 shared Amit MitraiD· 1 shared Clayton Clopton YatesiD· 1 shared Farnaz HemmatiiD· 1 shared Farshad AmiriiD· 1 shared Isra A. ElhussiniD· 1 shared Panagiotis MistriotisiD· 1 shared Robert D. ArnoldiD· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Ahmad-Bin Salam

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Molecular BiologybioRxivPreprintJul 20, 2022

Integrating pharmacogenomics data-driven prediction with bulk and single-cell RNAseq to demonstrate the efficacy of an NAMPT inhibitor against aggressive, taxane-resistant, and stem-like cells in lethal prostate cancer

Suman Mazumder, Taraswi Mitra Ghosh, Ujjal Kumar Mukherjee…·Amit Mitra

The paper uses scRNAseq and pharmacogenomics to identify FK866 as a potential drug for aggressive prostate cancer, showing its efficacy against drug-resistant and stem-like cells.

5 citations

humanbulk RNA-seq

𝕏 PostBluesky